Memo Therapeutics AG has reported complete Phase 2 results for potravitug, an investigational neutralising antibody for BK polyomavirus infection in kidney transplant recipients. The SAFE KIDNEY II study showed sustained reductions in viral load and improvement in biopsy-confirmed BK polyomavirus-associated nephropathy, although the trial did not achieve statistical significance on its primary endpoint of undetectable virus in blood at week 20.

Why the complete potravitug dataset strengthens the programme without erasing its primary endpoint miss

The most important feature of the SAFE KIDNEY II dataset is not the size of any single percentage difference. It is the tension between a negative primary analysis and several biologically consistent secondary signals pointing toward antiviral activity in both blood and kidney tissue.

The randomized, double-blind and placebo-controlled trial enrolled 95 kidney transplant recipients across 22 United States sites. Participants received four intravenous doses of potravitug or placebo at four-week intervals on top of the existing standard approach of reducing immunosuppressive treatment.

The main analysis asked whether potravitug could drive BK polyomavirus DNA in the blood below the assay’s lower limit of quantification by week 20. That occurred in 17.5% of patients receiving the 1,000 mg dose and 12.9% of placebo recipients. The difference was not statistically significant, meaning the trial did not prove success under the endpoint selected before the data were available.

That limitation should remain central to interpretation. A study that misses its primary endpoint cannot be converted into a positive pivotal trial simply by highlighting more favourable secondary measures. The result increases the probability that potravitug has biological activity, but it does not provide the clean confirmatory evidence normally expected for regulatory approval.

The longer-term findings nevertheless add credibility to the programme. At week 38, approximately 24.4% of treated patients had undetectable BK polyomavirus DNA compared with 13% of placebo recipients. Reductions exceeding two logarithmic units were recorded in 40.3% of the potravitug group and 24.7% of the placebo group.

These differences suggest that the antibody’s effect may continue developing after the four-dose treatment period ends. They also imply that complete viral clearance at week 20 may have been too stringent or too early to capture the treatment’s most relevant biological impact.

The pivotal challenge is now clear. Memo Therapeutics must select an endpoint that reflects clinically meaningful control of BK polyomavirus without appearing to redesign success around favourable findings discovered after the Phase 2 miss.

How potravitug targets BK polyomavirus without weakening transplant immunosuppression

BK polyomavirus commonly remains dormant after childhood infection. In kidney transplant recipients, the immunosuppressive medicines needed to prevent rejection can allow the virus to reactivate, multiply in the blood and spread into the transplanted kidney.

Current treatment depends mainly on reducing immunosuppression. Lowering the intensity of anti-rejection therapy may allow the patient’s immune system to regain control of the virus, but it exposes the transplanted kidney to a competing danger. The same immune recovery that helps clear BK polyomavirus may also attack the donor organ.

Potravitug is designed to change that trade-off. The fully human monoclonal antibody binds to the VP1 capsid protein on BK polyomavirus and is intended to block the virus from entering new cells. Laboratory work indicates that the antibody neutralises clinically relevant BK polyomavirus serotypes rather than targeting only one narrow viral variant.

A direct antiviral treatment could allow clinicians to control viral replication while maintaining sufficient immunosuppression to protect the transplanted kidney. That would represent a substantial advance over a strategy in which physicians must choose between infection progression and graft rejection.

SAFE KIDNEY II included immunosuppression reduction in both the active-treatment and placebo groups. Similar changes in immunosuppressive dosing were reported across the groups, supporting the interpretation that differences in viral outcomes were not simply caused by more aggressive immunosuppression withdrawal among potravitug recipients.

The antibody was given through four intravenous infusions spaced four weeks apart. This limited-course approach may be easier to integrate into transplant care than indefinite treatment, particularly if the antiviral effect persists for several months after the final infusion.

The unresolved issue is whether neutralising circulating virus is sufficient once infection has become established inside kidney tissue. Potravitug appears to reduce the ability of BK polyomavirus to infect additional cells, but it may still depend on the recipient’s immune system to eliminate cells that are already infected.

Why kidney-biopsy improvement may be more important than complete blood viral clearance

Blood polymerase chain reaction testing is central to BK polyomavirus monitoring because rising viral DNA can provide an early warning of infection. However, the outcome transplant clinicians ultimately want to prevent is damage to the transplanted kidney.

SAFE KIDNEY II was unusual because it included protocol-defined kidney biopsies at baseline and week 20, with central assessment using established pathological criteria. This allowed the study to examine whether changes in blood viral load were accompanied by changes inside the kidney.

Among patients receiving the 1,000 mg potravitug dose, biopsy-confirmed BK polyomavirus-associated nephropathy declined from 51.2% at baseline to 31.6% at week 20. The placebo group showed little change, moving from 23.8% to 24.4%.

The tissue findings are clinically interesting because they suggest that potravitug may affect the disease process rather than merely changing a laboratory value in the blood. Reducing the number of virus-infected tubular cells could plausibly protect kidney function and lower the risk of eventual graft loss.

The interpretation is complicated by the large baseline imbalance. More than half of the active-treatment group already had biopsy-confirmed nephropathy compared with fewer than one-quarter of placebo recipients. This gave the potravitug group more opportunity to demonstrate improvement and made a straightforward comparison between the final percentages unreliable.

A composite analysis combining at least a one-log reduction or undetectable viral DNA with the absence of biopsy-confirmed nephropathy favoured potravitug, with adjusted response rates of approximately 57% and 33% for active treatment and placebo. The reported odds ratio reached the boundary of nominal statistical significance.

This composite may reflect clinical reality more effectively than complete viral clearance alone. A patient whose viral load falls substantially and whose kidney biopsy no longer shows active BK polyomavirus damage may have received meaningful benefit even when a highly sensitive blood test continues to detect low-level virus.

However, composite endpoints can conceal uneven effects. A patient may qualify through viral-load reduction without tissue improvement, while another may improve histologically despite persistent DNAemia. The Phase 3 trial should report every component independently and establish which changes predict preservation of graft function.

What the week-38 findings reveal about durability after a short treatment course

Potravitug’s long-term signal is strategically important because the medicine was not administered continuously through week 38. Participants received four monthly infusions, followed by an extended observation period.

The increase in undetectable viral DNA from week 20 to week 38 suggests that the antiviral effect may continue after active dosing ends. A durable antibody concentration could keep neutralising new virus particles while infected cells are gradually cleared through natural immune mechanisms.

The time required for this process may explain why complete clearance at week 20 showed only a small separation from placebo. BK polyomavirus infection does not necessarily resolve immediately, especially when immunosuppression must be maintained to protect the transplanted kidney.

A sustained effect after four doses could support an attractive treatment model. Patients may receive a defined course rather than indefinite antiviral therapy, reducing cumulative treatment burden and potentially limiting cost.

Durability must eventually be measured through more than viral DNA. The decisive outcomes include kidney function, progression of fibrosis, acute rejection, donor-specific antibody formation, graft survival and the need to return to dialysis or undergo another transplantation.

A decline in viral load is valuable because persistent BK polyomavirus DNAemia is associated with nephropathy. It remains a surrogate for the harder clinical question of whether the treatment preserves the transplanted organ for longer.

The planned pivotal study will need enough follow-up to determine whether early antiviral responses translate into durable kidney protection rather than temporary laboratory improvement.

Why potravitug’s safety profile is encouraging but cannot yet settle rejection risk

Potravitug was generally tolerated during SAFE KIDNEY II. Most adverse events were mild or moderate, approximately 95% of participants completed all four administrations, and no treatment-related serious adverse events or adverse-event-related withdrawals were reported.

The absence of a major infusion or immune safety signal supports advancement into a larger trial. A medicine intended for transplant recipients must be especially tolerable because these patients are already medically vulnerable and receive several long-term therapies.

Infections were among the more frequently recorded adverse events, including COVID-19 and urinary tract infections. Investigators did not consider the overall pattern to represent a potravitug-specific safety concern, but a trial involving fewer than 100 people cannot exclude uncommon complications.

One participant experienced fatal histoplasmosis, which was considered a known but rare complication of immunosuppression rather than a treatment-related event. The case still illustrates the clinical fragility of the intended population and the difficulty of attributing infections when patients are receiving several immune-modifying medicines.

Rejection events were also observed, although many were borderline findings detected through protocol-required biopsies rather than clinically apparent episodes. Because immunosuppression reduction remains part of BK polyomavirus management, a future study must distinguish effects caused by the antibody from effects caused by changes to anti-rejection therapy.

The strongest safety claim potravitug could eventually support is not merely that the antibody causes few adverse reactions. It is that targeted antiviral treatment allows clinicians to control BK polyomavirus with less aggressive immunosuppression reduction and therefore less rejection risk.

SAFE KIDNEY II was not large enough to prove that advantage. Phase 3 must prospectively measure acute rejection, changes in immunosuppressive medicines, donor-specific antibodies and graft function alongside antiviral efficacy.

What SAFE KIDNEY 3 must change to turn supportive Phase 2 findings into approval evidence

Memo Therapeutics plans to initiate the pivotal SAFE KIDNEY 3 programme in 2026, with a proposed enrolment of approximately 240 patients across about 60 sites in the United States and Europe.

The first design requirement is a primary endpoint that is medically meaningful and statistically achievable. Complete viral clearance is easy to understand, but the Phase 2 results show that it may not capture the full tissue and virological benefit within a practical timeframe.

A composite involving substantial viral-load reduction and absence or resolution of BK polyomavirus-associated nephropathy could better reflect disease control. The components must be prespecified, independently assessed and supported by a clear explanation of why each matters to transplant outcomes.

Randomisation should be stratified according to baseline viral load, biopsy-confirmed nephropathy and other major risk factors. This would reduce the kind of imbalance seen in SAFE KIDNEY II, where far more potravitug recipients entered the trial with established kidney-tissue disease.

Immunosuppression changes must follow a standardised protocol or be captured with enough precision to support reliable adjustment. Physicians understandably individualise treatment according to rejection history and viral burden, but uncontrolled variation could obscure the antibody’s effect.

The Phase 3 programme should also include graft-function measures, rejection outcomes and longer-term follow-up. Regulators may accept virological and histological endpoints for initial approval, but clinicians and payers will ultimately want evidence that the medicine prevents graft deterioration and reduces costly transplant complications.

The primary endpoint miss gives Memo Therapeutics less room for ambiguity. The pivotal programme must confirm the specific signal identified in Phase 2 rather than produce another collection of favourable secondary analyses around an unsuccessful primary result.

How competition could challenge potravitug’s opportunity to become the first targeted therapy

Potravitug is among the most advanced candidates in a small but increasingly competitive BK polyomavirus treatment pipeline.

Vera Therapeutics has developed MAU868, another neutralising monoclonal antibody directed against the BK polyomavirus capsid protein. Early clinical work has supported the feasibility of antibody-based viral neutralisation, although MAU868 remains investigational.

AiCuris is pursuing a different strategy with AIC468, a splice-modulating antisense oligonucleotide intended to block production of a viral protein required for replication. That programme has moved beyond healthy-volunteer testing toward evaluation in kidney transplant recipients.

These approaches may eventually serve different stages of disease. A neutralising antibody could be most useful when infection is detected early and the objective is to prevent spread into additional kidney cells. An intracellular antiviral mechanism may offer advantages once active replication is established within tissue.

First-mover status will depend on pivotal execution rather than the age of the programme. Potravitug has Fast Track designation in the United States and orphan designation in the European Union, but neither designation guarantees approval.

Memo Therapeutics is privately held and will need substantial capital, manufacturing capability and commercial infrastructure to complete a multinational Phase 3 programme. Stronger data could attract a pharmaceutical partner capable of supporting global regulatory filings and a specialist transplant launch.

The commercial population is smaller than those for mass-market antivirals, but the value per treated patient could be significant because graft failure leads to dialysis, hospitalisation, retransplantation and major deterioration in quality of life.

Can potravitug become clinically transformative despite an imperfect Phase 2 result?

Potravitug addresses a real therapeutic gap. International treatment guidance continues to rely primarily on reducing maintenance immunosuppression, a strategy that can control the virus but increases the risk of rejection and does not directly neutralise BK polyomavirus.

SAFE KIDNEY II did not deliver an uncomplicated success. Complete viral clearance at the prespecified week-20 endpoint was only modestly higher with potravitug and failed to achieve statistical significance.

The broader dataset is more encouraging. Viral-load reductions were deeper, composite responses favoured treatment, biopsy-confirmed nephropathy declined and the antiviral signal persisted through week 38 without a treatment-related serious safety problem.

These findings are sufficient to justify a pivotal trial. They are not sufficient to declare potravitug a proven disease-modifying therapy.

The next study must show that the antibody produces a reproducible advantage under a prospectively defined endpoint and that viral control leads to better preservation of the transplanted kidney. It must also demonstrate that the treatment can reduce dependence on risky immunosuppression withdrawal rather than simply adding another infusion to the existing approach.

Memo Therapeutics has moved potravitug closer to a first targeted BK polyomavirus therapy. The decisive test is whether Phase 3 can convert a coherent but imperfect collection of signals into clear evidence that clinicians can trust when the survival of a transplanted kidney is at stake.

  BK polyomavirus, BK polyomavirus-associated nephropathy, kidney transplantation, Memo Therapeutics, potravitug, SAFE KIDNEY 3, SAFE KIDNEY II